Objective： The aim of the study was to evaluate the therapeutic effect and safety of whole-course three-dimensional conformal radiotherapy （3DCRT） combined with late-course accelerated hyperfractionated radiothera...Objective： The aim of the study was to evaluate the therapeutic effect and safety of whole-course three-dimensional conformal radiotherapy （3DCRT） combined with late-course accelerated hyperfractionated radiotherapy （LCAFR） on patients with esophageal carcinoma. Methods： one hundred and one patients with esophageal carcinoma were divided into two groups. Observing group （49 cases） were treated by whole-course 3DCRT. Patients in control group （52 cases） were treated by conventional radiotherapy. Clinical efficiencies and radiation toxicities were compared between two groups. Results： The side effects including radiation esophagitis （63.2%） and tracheitis （49.0%） decreased in observing group, but there was no significant difference between two groups （69.2% and 55.7% in controls）. The 1-, 2-and 3-year tumor local control rates and overall survival rates in the observing group were significantly improved compared with the control group, being respectively 87.8%, 75.5%, 63.3% vs 71.2%, 55.8%, 42.3% and 85.7%, 71.4%, 46.7% vs 69.2%, 51.9%, 26.9% （all P 0.05）. Conclusion： The therapeutic effect of whole-course 3DCRT combined with LCAFR for esophageal carcinomas is superior to conventional radiotherapy.展开更多
目的:分析肺鳞癌疾病患者治疗需求,评价直线加速器三维适形放疗治疗手段的预后效果。方法:选择2010年1月~2020年1月本院收治的130例肺鳞癌患者,经患者与家属知情同意、伦理委员会批准后进行随机分组治疗,对照组、观察组各65例。对照组...目的:分析肺鳞癌疾病患者治疗需求,评价直线加速器三维适形放疗治疗手段的预后效果。方法:选择2010年1月~2020年1月本院收治的130例肺鳞癌患者,经患者与家属知情同意、伦理委员会批准后进行随机分组治疗,对照组、观察组各65例。对照组患者采取常规放疗治疗,观察组患者采取直线加速器三维适形放疗治疗。比较2组肺鳞癌患者的生活质量、癌痛程度等情况,生活质量以欧洲癌症研究与治疗组织生活质量测定量表(european organzation for research and treatment of cancer quality of life-C30,EORTC QLQ-C30)评估,癌痛程度以视觉模拟评分法(Visual Analogue Scale/Score,VAS)评估。结果:观察组肺鳞癌患者近期疗效总有效率84.61%明显高于对照组,P<0.05;观察组肺鳞癌患者皮肤反应、消化道反应等不良反应发生率9.23%明显低于对照组,P<0.05;观察组患者生活质量评分高于对照组,P<0.05;观察组患者癌痛程度评分低于对照组,P<0.05。结论:直线加速器三维适形放疗治疗肺鳞癌患者近期疗效好、安全性高,有助于提升患者的生活质量、减轻癌痛。展开更多
文摘Objective： The aim of the study was to evaluate the therapeutic effect and safety of whole-course three-dimensional conformal radiotherapy （3DCRT） combined with late-course accelerated hyperfractionated radiotherapy （LCAFR） on patients with esophageal carcinoma. Methods： one hundred and one patients with esophageal carcinoma were divided into two groups. Observing group （49 cases） were treated by whole-course 3DCRT. Patients in control group （52 cases） were treated by conventional radiotherapy. Clinical efficiencies and radiation toxicities were compared between two groups. Results： The side effects including radiation esophagitis （63.2%） and tracheitis （49.0%） decreased in observing group, but there was no significant difference between two groups （69.2% and 55.7% in controls）. The 1-, 2-and 3-year tumor local control rates and overall survival rates in the observing group were significantly improved compared with the control group, being respectively 87.8%, 75.5%, 63.3% vs 71.2%, 55.8%, 42.3% and 85.7%, 71.4%, 46.7% vs 69.2%, 51.9%, 26.9% （all P 0.05）. Conclusion： The therapeutic effect of whole-course 3DCRT combined with LCAFR for esophageal carcinomas is superior to conventional radiotherapy.
基金Supported by Shantou University Medical College Clinical Research Enhancement Initiative,and Research and Travel Grants from the Science and Technology Key Project of Shantou City,China,2012,No.2012-165-131
文摘AIM: To establish the feasibility of simultaneous modulated accelerated radiation therapy (SMART) in esophageal cancer (EC).
文摘目的:分析肺鳞癌疾病患者治疗需求,评价直线加速器三维适形放疗治疗手段的预后效果。方法:选择2010年1月~2020年1月本院收治的130例肺鳞癌患者,经患者与家属知情同意、伦理委员会批准后进行随机分组治疗,对照组、观察组各65例。对照组患者采取常规放疗治疗,观察组患者采取直线加速器三维适形放疗治疗。比较2组肺鳞癌患者的生活质量、癌痛程度等情况,生活质量以欧洲癌症研究与治疗组织生活质量测定量表(european organzation for research and treatment of cancer quality of life-C30,EORTC QLQ-C30)评估,癌痛程度以视觉模拟评分法(Visual Analogue Scale/Score,VAS)评估。结果:观察组肺鳞癌患者近期疗效总有效率84.61%明显高于对照组,P<0.05;观察组肺鳞癌患者皮肤反应、消化道反应等不良反应发生率9.23%明显低于对照组,P<0.05;观察组患者生活质量评分高于对照组,P<0.05;观察组患者癌痛程度评分低于对照组,P<0.05。结论:直线加速器三维适形放疗治疗肺鳞癌患者近期疗效好、安全性高,有助于提升患者的生活质量、减轻癌痛。
